Disptaches from Vitafoods Europe 2011

DSM on Vitatene, Martek and its investment “shortlist”

By Shane Starling

- Last updated on GMT

Related tags: Health, Martek biosciences

DSM’s head of global marketing in human nutrition and health, Gareth Barker, explains why it has bought a carotenoid supplier (approval permitting), how the Martek acquisition is progressing, and why the company is not finished spending yet.

Barker outlined why the Vitatene offer, which is subject to regulatory approval, fitted with DSM Nutritional Product’s ‘natural’ strategy, which also motivated the Martek Biosciences buy-out last year.

Going forward, “we are always looking at new acquisitions” ​Morgan stated. “We have a shortlist which will fit our strategic direction – we’re always looking for all opportunities within our arena. But who and when only time will tell.”

Related news

Show more

Related products

show more

DailyZz™ - Wake-up to the difference

DailyZz™ - Wake-up to the difference

Kemin Health Europe | 06-May-2021 | Data Sheet

Did you know that more than half of European consumers are unsatisfied with the daily amount of sleep and sleep quality? Quality sleep is essential for...

Related suppliers

Follow us


View more